Some areas of AAO.org are temporarily unavailable. We apologize for the inconvenience and are working to restore access.

  •   
    AAO 2017
    04:45
    Cataract/Anterior Segment, Complications, Comprehensive Ophthalmology

    In this interview from AAO 2017, Dr. David Chang discusses compelling evidence supporting the efficacy of intracameral moxifloxacin as endophthalmitis prophylaxis. Using records from more than 1 million consecutive cataract surgeries performed at Aravind Eye Hospitals in India, Dr. Chang and his colleagues found the infection rate dropped significantly after the adoption of a standardized prophylaxis protocol. The rate of endophthalmitis at the Aravind Hospitals is now less than half of the national average in America. For physicians who wish to use moxifloxacin, Dr. Chang recommends undiluted Vigamox (Novartis), or having it compounded by a 503B pharmacy.  

    Relevant Financial Disclosures: None